Correlation of CD133 and SOX2 Expression with Regional Lymph Nodes Metastatic Status in Invasive Breast Carcinoma of No Special Type

Dyah Fauziah, Sutrisno Sutrisno, Gondo Mastutik

Abstract


Background: CD133 overexpression can increase cell proliferation, migration, and epithelialmesenchymal transition that promotes metastasis. CD133 expression is induced by hypoxiainduced factor (HIF) which requires SOX2 binding in the promoter region. SOX2 is an embryonal transcription factor that plays a role in the development of malignancy. The study aimed to analyze the expression of CD133 and SOX2 with regional lymph nodes (LN) metastatic status in invasive breast carcinoma of no special type (NST).

Methods: The study was a cross-sectional design. Forty-five samples were retrieved from pathology archives in Dr. Soetomo Hospital from January to December 2018. Samples were divided into 2 groups, with and without regional LN metastasis. Immunohistochemistry with CD133 and SOX2 was applied to all samples. CD133 expression was assessed by immunoreactive score, and SOX2 expression was assessed by the percentage of tumor positive cells.

Results: There was no significant difference in CD 133 expression between invasive breast carcinoma of NST with and without regional LN metastases (P = .990). A positive correlation was found in SOX2 expression between breast carcinoma with and without regional LN metastasis (P = .000; rs = .518). There was no correlation between CD133 and SOX2 expression (P = .082), which means that the high expression of CD133 did not affect SOX2 expression.

Conclusions: CD133 expression was not significantly different in breast carcinoma with and without LN metastasis. The high expression of SOX2 was found significantly correlated with regional LN metastasis. SOX2 expression may become a potential prognostic marker in invasive breast carcinoma of NST. regional LN metastasis


Keywords


breast cancer, invasive breast carcinoma of NST, CD133, SOX2, regional LN metastasis

References


Bellanger M, Zeinomar N, Tehranifar P, Terry MB. Are global breast cancer incidence and mortality patterns related to country spesific economic development and prevention strategies?. J Glob Oncol. 2018;4:1-16.

GLOBOCAN. International Agency for Research on Cancer. World Health Organization. 2018.

Kementerian Kesehatan RI. Kanker payudara. Infodatin Pusat Data dan Informasi Kementerian Kesehatan RI. 2016.

Li X, Xu Y, Chen Y, et al. SOX2 promotes tumor metastasis by stimulating epithelial-to-mesenchymal transition via regulation of WNT/ß-catenin signal network. Cancer Lett. 2013;336(2):379-89.

Han L, Gao X, Gu X, et al. Prognostic significance of cancer stem cell marker CD133 expression in breast cancer. Int J Clin Exp Med. 2017;10(3):4829-37.

Li Z. CD133: a stem cell biomarker and beyond. Exp Hematol Oncol. 2013;2(1):17.

Glumac PM, Lebeau AM. The role of CD133 in cancer : a concise review. Clin Transl Med. 2018;7:18.

Lida H, Suzuki M, Goitsuka R, Ueno H. Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2. Int J Oncol. 2012;40:71-9.

Liou G. CD133 as a regulator of cancer metastasis through the cancer stem cells. Int J Biochem Cell Biol. 2019;106:1-7.

Lengerke C, Fehm T, Kurth R, et al. Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma. BMC Cancer. 2011;11:42.

Mehta GA, Khanna P, Gatza ML. Emerging role of SOX2 proteins in breast cancer development and maintenance. J Mammary Gland Biol Neoplasia. 2019;24(3):213-30.

Bock C, Kuhn C, Ditsch N, et al. Strong correlation between N-cadherin and CD133 in breast cancer: role of both markers in metastatic events. J Cancer Res Clin Oncol. 2014;140:1873–81.

Behrooz AB, Syahir A, Ahmad S. CD133: beyond a cancer stem cell biomarker. Journal of Drug Targeting. 2019;27(3):257-69.

Aghajani M, Mansoori B, Mohammadi A, et al. New emerging roles of CD133 in cancer stem cell: signaling pathway and miRNA regulation. Cell Physiol. 2019;234(12):21642-61.

Tume L, Paco K, Ubidia-Incio R, Moya J. CD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapy. Gaceta Mexicana De Oncologia. 2016;15(1):22-30.

Zhao P, Lu Y, Jiang X, Li X., Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Cancer Sci. 2011;102(5):1107-11.

Abdelrahman AE, Ibrahim HM, Elsebai EA, et al. The clinicopathological significance of CD133 and SOX2 in astrocytic glioma. Cancer Biomark. 2018;23:391-403.

Xiao Z-Y, Chen X-J, Pan Q, et al. Expression of nestin, CD133 and SOX2 in meningiomas. Turk Neurosurg. 2018;28(6):910-14.

Zhao W, Qin Y, Wu X, et al. Correlation of CD133, E-cadherin, and ß-catenin with metastasis and prognosis in esophageal squamous cell carcinoma. Int J Clin Exp Med. 2018;11(9):8583-9592.

Li C, Li Y, Xing Y, et al. The interaction between cancer stem cell marker CD133 and Src protein promotes focal adhesion kinase (FAK) phosphorylation and cell migration. The J Biol Chem. 2016;291(30):15540-50.

Jang J, Song Y, Kim S, et al. Potential mechanism of CD133 in cancer stem cells. Life Sci. 2017;184:25-29.

Aghajani M, Mansoori B, Mohammadi A, et al. New emerging roles of CD133 in cancer stem cell: signaling pathway and miRNA regulation. J Cell Physiol. 2019;234(12):21642-61.

Mansouri S, Nejad R, Karabork M, et al. SOX2: regulation of expression and contribution to brain tumors. CNS Oncology. 2016;5(3):159-73.

Neumann J, Bahr F, Horst D, et al. SOX2 expression correlates with lymph-node metastasis and distant spread in right-sided colon cancer. BMC Cancer. 2011;11: 518.

Gao H, Teng C, Huang W, Peng J, Wang C. SOX2 promotes the epithelial to mesenchymal transition of esophageal squamous cells by modulating slug expression through the activation of STAT3/HIF-α signaling. Int J Mol Sci. 2015;16(9):21643-657.

Liu X, Qiao B, Zhao T, et al. SOX2 promotes tumor agressivenes and epithelial-mesenchymal transition in tongue squamous cell carcinoma. Int J Mol Med. 2018;42(3):1418-26.

Wang H, Xie J. The role of SOX2 in angiogenesis in breast cancer. Int J Clin Exp Pathol. 2018;11(5):2805-10.

Liu P, Tang H, Song C, et al. SOX2 promotes cell proliferation and metastasis in triple negative breast cancer. Front Pharmacol. 2018;9:942.

Saigusa S, Tanaka K, Toiyama Y, et al. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemotherapy. Ann Surg Oncol. 2009;16(12):3488-98.

Konishi H, Asano N, Imatani A, et al. Notch1 directly induced CD133 expression in human diffuse type gastric cancers. Oncotarget. 2016;7(35):56598-607.


Full Text: PDF

DOI: 10.33371/ijoc.v15i1.750

Article Metrics

Abstract view : 22 times
PDF - 19 times

Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 Indonesian Journal of Cancer

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.